Jill DeSimone
Known title: DirectorCIK: 0001930479
Jill DeSimone's purchase track record
Jill DeSimone has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/5/2023 | PRAX | $25K | +9.6% | +105.0% | +20.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PRAX | ▲ Buy | Option Exercise | 8,566 | $379K | 6/24/2026 | View on chart |
| PRAX | ▲ Buy | Option Exercise | 3,034 | $447K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 120 | $36K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 320 | $98K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 683 | $210K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 1,750 | $544K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 2,854 | $890K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 1,004 | $314K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 504 | $158K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 837 | $264K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 1,240 | $382K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 1,279 | $403K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 999 | $309K | 6/24/2026 | View on chart |
| PRAX | ▼ Sell | Open Market | 10 | $3K | 6/24/2026 | View on chart |
| PRAX | ▲ Buy | Grant | 1,371 | $0 | 6/10/2026 | View on chart |
| PRAX | ▲ Buy | Open Market | 14,500 | $25K | 10/5/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule
Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.